The present study has revealed anincreased expression of the BCR::ABL/p210 oncogene and two mutations in theBCR::ABL kinase domain in a patient with B-ALL (Ph+) after dasatinib therapy.The first one, the F317L point mutation, is well-known; and the secondmutation, a new insertion of nine nucleotides, has not been describedpreviously. The gene discussed is EVPL; the disease is acute lymphoblastic leukemia.